Antimicrobial Susceptibility Testing

Laboratory antimicrobial susceptibility reports:

Where possible, antimicrobial susceptibilities are determined and reported in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST). This is a system that has researched and validated the links between the in-vitro laboratory tests and the clinical outcomes. However, this evaluation in ongoing and for some antibiotic-bacterial combinations the data is absent of not definitive. In these circumstances in-vitro testing and empirical experience has been considered, and a decision to report the susceptibility has been made following current clinical guidance.

Note the antibiotic-bacterial combinations not supported by EUCAST methodology include:

Trimethoprim – Staphylococcal infections (other that S. saprophyticus for UTI)
Doxycycline – Enterobacteriaceae (Coliforms)
Doxycycline – Enterococci
Daptomycin – Enterococci
Fosfomycin – Any organism (other than E. coli in UTI)
Neisseria gonorrhoea – Tested by BSAC methodology and referred to reference lab if required
Neisseria meningitidis – Tested by BSAC methodology and referred to reference lab if required
Anaerobic infectinos – Tested by BSAC methodology
Colistin – Not routinely tested, but if needed would be sent to the reference lab for MIC testing

Burkholderia cepacia complex and Pseudomonas aeruginosa from Cystic Fibrosis (CF) patients.

Please note with B. cepacia complex and P. aeruginosa infections of Cystic Fibrosis (CF) patients, there is insufficient evidence to link in-vitro laboratory testing and clinical outcome.

Specimen Labelling Procedure